Multiple Sclerosis Clinical Trial
Official title:
An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis
Verified date | June 2012 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Regional Ethical Review Board |
Study type | Interventional |
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis. The Extension study was an extension to the 24-month Core study (CFTY720D2301/NCT00289978).
Status | Completed |
Enrollment | 920 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years to 58 Years |
Eligibility |
Inclusion Criteria: - Patients should complete the 24 month core study Exclusion Criteria: - Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc. - Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Novartis Investigative Site | Chatswood | |
Australia | Novartis Investigative Site | Fitzroy | |
Australia | Austin Health, Department of Neurology | Heidelberg | |
Australia | Novartis Investigative Site | North Gosford | |
Australia | Novartis Investigative Site | Woodville | |
Belgium | Novartis Investigative Site | Brugge | |
Belgium | Novartis Investigative Site | Bruxelles | |
Belgium | Novartis Investigative Site | Charleroi | |
Belgium | Novartis Investigative Site | Leuven | |
Belgium | Novartis Investigative Site | Overpelt | |
Belgium | Novartis Investigative Site | Sijsele - Damme | |
Belgium | Novartis Investigative Site | Sint-Truiden | |
Canada | Novartis Investigative Site | Halifax | |
Canada | Novartis Investigative Site | Kingston | |
Canada | Novartis Investigative Site | London | |
Canada | Novartis Investigative Site | Montreal | |
Canada | Novartis Investigative Site | Nepean | |
Canada | Novartis Investigative Site | Regina | |
Canada | Novartis Investigative Site | Toronto | |
Canada | Novartis Investigative Site | Vancouver | |
Czech Republic | Novartis Investigative Site | Brno | |
Czech Republic | Novartis Investigative Site | Olomouc | |
Czech Republic | Novartis Investigative Site | Ostrava-Poruba | |
Czech Republic | Novartis Investigative Site | Pardubice | |
Czech Republic | Novartis Investigative Site | Plzen - Lochotin | |
Czech Republic | Novartis Investigative Site | Prague 5 | |
Czech Republic | Novartis Investigative Site | Praha 2 | |
Czech Republic | Novartis Investigative Site | Rychnov nad Kneznou | |
Czech Republic | Novartis Investigative Site | Teplice | |
Estonia | Novartis Investigative Site | Talinn | |
Finland | Novartis Investigative Site | Helsinki | |
Finland | Novartis Investigative Site | Tampere | |
Finland | Novartis Investigative Site | Turku | |
France | Novartis Investigative Site | Clermont Ferrand Cedex | |
France | Novartis Investigative Site | Dijon | |
France | Novartis Investigative Site | Lille Cedex | |
France | Novartis Investigative Site | Marseille cedex 05 | |
France | Novartis Investigative Site | Montpellier cedex 5 | |
France | Novartis Investigative Site | Nantes | |
France | Novartis Investigative Site | Paris Cedex 13 | |
France | Novartis Investigative Site | Rennes | |
France | Novartis Investigative Site | Strasbourg | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Duesseldorf | |
Germany | Novartis Investigative Site | Gießen | |
Germany | Novartis Investigative Site | Hamburg | |
Germany | Novartis Investigative Site | Leipzig | |
Germany | Novartis Investigative Site | Magdeburg | |
Germany | Novartis Investigative Site | Muenchen | |
Germany | Novartis Investigative Site | Muenster | |
Germany | Novartis Investigative Site | Regensburg | |
Germany | Novartis Investigative Site | Stuttgart | |
Germany | Novartis Investigative Site | Tübingen | |
Greece | Novartis Investigative Site | Athens | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Miskolc | |
Hungary | Novartis Investigative Site | Szekesfehervar | |
Ireland | Novartis Investigative Site | Dublin 4 | |
Israel | Novaratis Investigative Site | Ashkelon | |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Ramat Gan | |
Israel | Novartis Investigative Site | Safed | |
Netherlands | Novartis Investigative Site | Amsterdam | |
Netherlands | Novartis Investigative Site | Nieuwegein | |
Netherlands | Novartis Investigative Site | Nijmegen | |
Netherlands | Novartis Investigative Site | Rotterdam | |
Netherlands | Novartis Investigative Site | Sittard | |
Netherlands | Novartis Investigative Site | Tilburg | |
Poland | Novartis Investigative Site | Bialystok | |
Poland | Novartis Investigative Site | Gdansk | |
Poland | Novartis Investigative Site | Katowice | |
Poland | Novartis Investigative Site | Lodz | |
Poland | Novartis Investigative Site | Poznan | |
Poland | Novartis Investigative Site | Warsaw | |
Poland | Novartis Investigative Site | Warszawa | |
Romania | Novartis Investigative Site | Bucharest | |
Romania | Novartis Investigative Site | Craiova | |
Romania | Novartis Investigative Site | Lasi | |
Romania | Novartis Investigative Site | Tg. Mures | |
Russian Federation | Novartis Investigative Site | Kazan | |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | St. Petersburg | |
Slovakia | Novartis Investigational Site | Bratislava | |
Slovakia | Novartis Investigative Site | Martin | |
Slovakia | Novartis Investigational Site | Zilina | |
South Africa | Novartis Investigational Site | Cape Town | |
South Africa | Novartis Investigational Site | Rosebank | |
South Africa | Novartis Investigational Site | Umhlanga | |
Sweden | Novartis Investigational Site | Göteborg | |
Sweden | Novartis Investigational Site | Stockholm | |
Switzerland | Novartis Investigative Site | Lausanne | |
Switzerland | Novartis Investigative Site | Zuerich | |
Turkey | Novartis Investigational Site | Ankara | |
Turkey | Novartis Investigational Site | Bursa | |
Turkey | Novartis Investigational Site | Cerrahpasa/Istanbul | |
Turkey | Novartis Investigational Site | Gaziantep | |
Turkey | Novartis Investigational Site | Istanbul | |
Turkey | Novartis Investigational Site | Izmir | |
Turkey | Novartis Investigational Site | Mersin | |
Turkey | Novartis Investigational Site | Yenisehir/Izmir | |
United Kingdom | Novartis Investigative Site | Bristol | |
United Kingdom | Novartis Investigative Site | London | |
United Kingdom | Novartis Investigative Site | Newcastle Upon Tyne | |
United Kingdom | Novartis Investigative Site | Nottingham | |
United Kingdom | Novartis Investigative Site | Sheffield |
Lead Sponsor | Collaborator |
---|---|
Novartis |
Australia, Belgium, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Sweden, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study) | ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. | Months 0 to end of study (maximum up to 60 months) | No |
Primary | Time to First Confirmed Relapse up to End of Study: Kaplan-Meier Estimate of Percentage of Patients Relapse-free | A relapse was confirmed when it was accompanied by an increase of at least half a step (0.5) on the Expanded Disability Status Scale (EDSS) or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Kaplan-Meier estimates of the percentage of relapse-free patients at end of study and and 95% confidence intervals (CIs) were presented for the treatment groups. | Core baseline to end of study (maximum up to 60 months) | No |
Primary | Annualized Aggregate Relapse Rate (ARR) During Months 0-24 (Core Study) and Months 24-48 (Extension Study) | ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. | Months 0-24 (core study) and Months 24-48 (extension study) | No |
Primary | Change (Expressed as Ratio) in the Annualized Aggregate Relapse Rate (ARR) From Months 0-24 (Core Study) to Months 24-48 (Extension Study) | ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. | Months 0-24 (core study) and Months 24-48 (extension study) | No |
Secondary | Change in Mean Number of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study) | The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis. | Months 0-24 (core study) and Months 24-48 (extension study) | No |
Secondary | Percentage of Patients Free of New or Newly Enlarged T2 Magnetic Resonance Imaging (MRI) Lesions During Months 0-24 (Core Study) and Months 24-48 (Extension Study) | The number of new or newly enlarged T2 lesions was assessed with T2-weighted MRI scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2 weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis. | Months 0-24 (core study) and Months 24-48 (extension study) | No |
Secondary | Percent Change in Brain Volume From Month 0 to Month 24 (Core Study) and From Month 24 to Month 48 (Extension Study) | Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change. | Months 0-24 (core study) and Months 24-48 (extension study) | No |
Secondary | Percent Change in Brain Volume From Month 0 End of Study (Core and Extension Study) | Calculations of brain volume change were performed using the structural image evaluation of normalized atrophy (SIENA), software included in the Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library. SIENA is a fully automated method for estimating temporal brain volume change. | Months 0 to end of study (maximum up to 60 months) | No |
Secondary | Time to First 3-month Confirmed Disability Progression up to End of Study Based on Expanded Disability Status Scale (EDSS): Kaplan-Meier Estimate of Percentage of Patients Free of Disability Progression | Kurtzke's Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in multiple sclerosis (MS) includes a series of scores in each of eight functional systems such as Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, Cerebral, and Other. The EDSS steps range from 0 (normal) to 10 (death due to MS). The Kaplan-Meier estimates of the percentage of participants free of disability progression at end of study and their 95% CIs were provided for each treatment group. | Core baseline to end of study (maximum up to 60 months) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|